Por favor, use este identificador para citar o enlazar este ítem:
http://hdl.handle.net/10637/15055
Registro completo de metadatos
Campo DC | Valor | Lengua/Idioma |
---|---|---|
dc.contributor.other | UCH. Departamento de Farmacia | - |
dc.creator | Castillo García, Encarnación | - |
dc.creator | Dea Ayuela, María Auxiliadora | - |
dc.creator | Bolás Fernández, Francisco | - |
dc.creator | Rangel, M. | - |
dc.creator | González Rosende, María Eugenia | - |
dc.date.accessioned | 2024-01-23T09:02:27Z | - |
dc.date.available | 2024-01-23T09:02:27Z | - |
dc.date.issued | 2010 | - |
dc.identifier.citation | Castillo, E., Dea-Ayuela, M.A., Bolás-Fernández, F., Rangel, M. & González-Rosende, M.E. (2010). The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives. Current Medicinal Chemistry, vol. 17, i. 33, pp. 4027–4051. DOI: https://doi.org/10.2174/092986710793205345 | es_ES |
dc.identifier.issn | 0929-8673 | - |
dc.identifier.issn | 1875-533X (Electrónico) | - |
dc.identifier.uri | http://hdl.handle.net/10637/15055 | - |
dc.description | Este recurso no está disponible en acceso abierto por política de la editorial. | - |
dc.description.abstract | Leishmaniasis, African sleeping sickness and Chagas disease, caused by the kinetoplastid parasites Leishmania spp, Trypanosoma brucei and Trypanosoma cruzi, respectively, are among the most important parasitic diseases, affecting millions of people and considered to be within the most relevant group of neglected tropical diseases. The main alternative to control such parasitosis is chemotherapy. Nevertheless, the current chemotherapeutic treatments are far from being satisfactory. This review outlines the current understanding of different drugs against leishmaniasis, African sleeping sickness and Chagas disease, their mechanism of action and resistance. Recent approaches in the area of anti-leishmanial and trypanocidal therapies are also enumerated, new modulators from the mode of action, development of new formulations of old drugs, therapeutic switching and “in silico” drug design. | es_ES |
dc.language.iso | en | es_ES |
dc.relation | UCH. Financiación Autonómica | - |
dc.relation | UCH. Financiación Universidad | - |
dc.relation | Este artículo de investigación ha sido financiado por la Generalitat Valenciana (AP-116/09) y por la Universidad CEU Cardenal Herrera (PRCEU-UCH08-07). | - |
dc.relation.ispartof | Current Medicinal Chemistry, vol. 17, i. 33 | - |
dc.rights | http://creativecommons.org/licenses/by-nc-nd/4.0/deed.es | - |
dc.subject | Farmacología | - |
dc.subject | Pharmacology | - |
dc.subject | Medicamento | - |
dc.subject | Drugs | - |
dc.subject | Tratamiento médico | - |
dc.subject | Medical treatment | - |
dc.subject | Enfermedad transmisible | - |
dc.subject | Infectious diseases | - |
dc.title | The kinetoplastid chemotherapy revisited: current drugs, recent advances and future perspectives | es_ES |
dc.type | Artículo | es_ES |
dc.identifier.doi | https://doi.org/10.2174/092986710793205345 | - |
dc.relation.projectID | AP-116/09 | - |
dc.relation.projectID | PRCEU-UCH08-07 | - |
dc.centro | Universidad Cardenal Herrera-CEU | - |
Aparece en las colecciones: | Dpto. Farmacia |
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.